Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL FRUMOVITZ and ANIL K SOOD.
Connection Strength
2.098
-
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol. 2007 Mar; 104(3):768-78.
Score: 0.291
-
Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer. Obstet Gynecol. 2023 05 01; 141(5):1019-1023.
Score: 0.222
-
Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res. 2021 08 01; 27(15):4450.
Score: 0.198
-
Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstet Gynecol. 2019 12; 134(6):1253-1259.
Score: 0.176
-
PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Mol Cancer Ther. 2019 01; 18(1):162-172.
Score: 0.163
-
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer. Gynecol Oncol. 2014 Jul; 134(1):6-9.
Score: 0.121
-
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6532-43.
Score: 0.115
-
Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. Obstet Gynecol. 2012 Mar; 119(3):504-8.
Score: 0.103
-
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res. 2011 Aug 15; 17(16):5367-78.
Score: 0.098
-
Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010 Jun; 117(3):491-6.
Score: 0.090
-
Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010 Feb 01; 116(3):625-30.
Score: 0.089
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.070
-
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors. Am J Obstet Gynecol. 2024 05; 230(5):544.e1-544.e13.
Score: 0.059
-
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors. Am J Obstet Gynecol. 2023 06; 228(6):724.e1-724.e9.
Score: 0.055
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.050
-
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
Score: 0.043
-
Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecol Oncol. 2019 01; 152(1):101-105.
Score: 0.041
-
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
Score: 0.040
-
Proceedings from the 9th International Conference on Ovarian Cancer. Gynecol Oncol. 2012 Apr; 125(1):5-7.
Score: 0.025
-
Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.
Score: 0.025
-
Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010 Aug; 116(2 Pt 1):269-273.
Score: 0.023